Methotrexate Cipla

Methotrexate, the active ingredient in Methotrexate Cipla, is a folate antagonist presented as an oral formulation for oral use. It is employed in the management of rheumatoid arthritis, psoriasis, and several neoplastic diseases, including acute lymphoblastic leukemia and osteosarcoma, by targeting rapidly dividing cells.

GNH USA supplies Methotrexate Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use across EU and other markets.

Methotrexate is a folate antagonist used in several autoimmune and oncologic disease pathways. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell proliferation, improving plaque severity. - Acute lymphoblastic leukemia: interferes with malignant cell replication, contributing to remission. - Osteosarcoma: used as part of combination chemotherapy to inhibit tumor growth.

Methotrexate may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea and vomiting: gastrointestinal upset often occurring early in therapy. - Fatigue: persistent tiredness affecting daily activities. - Mouth sores: ulceration of oral mucosa. Serious or Rare Side Effects: - Severe liver toxicity: potential for hepatitis or fibrosis with prolonged use. - Pulmonary toxicity: interstitial pneumonitis presenting with cough and dyspnea. - Bone marrow suppression: severe pancytopenia requiring medical intervention.

When prescribing methotrexate, several precautions should be observed to minimize risks. - Baseline testing: obtain liver function, renal function and complete blood count before initiation. - Monitoring: schedule regular laboratory assessments to detect hepatotoxicity or cytopenias. - Concomitant drugs: avoid use with other folate antagonists or nephrotoxic agents. - Pregnancy: contraindicated in pregnancy; ensure effective contraception for women of childbearing potential. - Patient education: advise on signs of infection, liver issues, and pulmonary symptoms. - Store at ambient temperature: keep tablets in original container, protect from moisture and heat.

Methotrexate has notable drug interactions that can alter its efficacy or increase toxicity. Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can increase methotrexate serum levels and risk renal toxicity. - Proton pump inhibitors (PPIs): may reduce renal clearance, enhancing toxicity. - Trimethoprim‑sulfamethoxazole: synergistic folate antagonism leading to severe myelosuppression. Moderate Interactions (Monitor Closely): - Azathioprine or other immunosuppressants: combined immunosuppression may raise infection risk. - Live vaccines: reduced efficacy and potential for infection. - Vitamin supplements containing folic acid: may diminish therapeutic effect, requiring dose adjustment.